Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 1.00 |
| ▸ | IL2 | P60568 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleuropein SCHEMBL22220681 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL14209775 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL22598615 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL23559534 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL18843179 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL23133255 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL23133256 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL24452037 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL22220678 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E | |
| Oleuropein SCHEMBL17934321 | 1.00 | BACE1 (1.00) | BACE1IL2POLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | BACE1 780/4885IL2 1883/4885POLB 1395/4885 |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | KRAS, G3BP1, NRAS | BACE1 1105/4885IL2 1406/4885POLB 3857/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | BACE1 780/4885IL2 1883/4885POLB 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.